Belinostat

CAS No. 866323-14-0

Belinostat( PXD101 | PX105684 | PXD-101 | PXD 101 | PX-105684 )

Catalog No. M16294 CAS No. 866323-14-0

A potent HDAC inhibitor with IC50 of 27 nM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
10MG 58 Get Quote
50MG 133 Get Quote
100MG 197 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Belinostat
  • Note
    Research use only, not for human use.
  • Brief Description
    A potent HDAC inhibitor with IC50 of 27 nM.
  • Description
    A potent HDAC inhibitor with IC50 of 27 nM (HeLa cell extracts); inhibits histone deacetylase activity in cell lysates with IC50 of 9-100 nM, increases the acetylation of histone H4 and induces apoptosis in tumor cell lines; inhibits the growth of a range of human tumor cell lines in vitro (IC50=0.2-3.4 uM); shows antitumor activity in vivo with no apparent toxicity.Blood Cancer Approved.
  • In Vitro
    Belinostat (PXD101) induces a concentration-dependent (0.2-5 μM) increase in acetylation of histone H4 in tumor cell lines. Belinostat is cytotoxic in vitro in a number of tumor cell lines with IC50s in the range 0.2-3.4 μM as determined by a clonogenic assay and induces apoptosis. Belinostat inhibits the growth of a number of human tumor cell lines in vitro with IC50s determined by a clonogenic assay in the range 0.2-3.4 μM. Belinostat (PXD101) is a potent histone deacetylase (HDAC) inhibitor, potently inhibits the enzymatic activity of purified recombinant HDAC6 (IC50 of 82 nM).
  • In Vivo
    Treatment of nude mice bearing human ovarian and colon tumor xenografts with Belinostat (10-40 mg/kg/day i.p.) daily for 7 days causes a significant dose-dependent growth delay with no obvious signs of toxicity to the mice. Growth delay is also observed for xenografts of cisplatin-resistant ovarian tumor cells. A marked increase in acetylation of H4 is detected in blood and tumor of mice 3 h after treatment with Belinostat (PXD101). The inhibition of growth of human tumor xenografts in mice, with no apparent toxicity. Belinostat (PXD101) displays single-agent antitumor activity on human A2780 ovarian cancer s.c. xenografts which is enhanced via combination therapy with Carboplatin.
  • Synonyms
    PXD101 | PX105684 | PXD-101 | PXD 101 | PX-105684
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    HDAC
  • Recptor
    HDAC
  • Research Area
    Cancer
  • Indication
    Blood cancer

Chemical Information

  • CAS Number
    866323-14-0
  • Formula Weight
    318.3477
  • Molecular Formula
    C15H14N2O4S
  • Purity
    >98% (HPLC)
  • Solubility
    10 mM in DMSO
  • SMILES
    O=C(NO)/C=C/C1=CC=CC(S(=O)(NC2=CC=CC=C2)=O)=C1
  • Chemical Name
    2-Propenamide, N-hydroxy-3-[3-[(phenylamino)sulfonyl]phenyl]-, (2E)-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Plumb JA, et al. Mol Cancer Ther. 2003 Aug;2(8):721-8. 2. Qian X, et al. Mol Cancer Ther. 2006 Aug;5(8):2086-95. 3. Buckley MT, et al. J Transl Med. 2007 Oct 12;5:49.
molnova catalog
related products
  • Pandacostat

    Pandacostat is the first nonselective HDAC inhibitor (pan-HDACi).

  • TYA-018

    TYA-018 is an orally available and selective HDAC6 inhibitor with cardioprotective properties for the study of dilated heart disease and heart failure.TYA-018 prevents sarcomere damage and decreases Nppb expression.

  • Resminostat

    A potent inhibitor of HDAC1/3/6 with IC50s of 43-72 nM.